Olink Holding AB (publ) announced several appointments in its leadership structure. Olink Chief Commercial Officer (CCO) Carl Raimond will be appointed President, effective upon the hiring of a new CCO, which is expected by the end of the year. In the interim, Carl will continue his strong stewardship of the commercial organization during Olink's second half of 2022 and lead the transition of CCO duties.

In this newly created position, Carl's role will expand from leadership of the commercial group to responsibility for corporate functions, while continuing to report to CEO Jon Heimer. In addition, Anna Marsell will become Chief Operating Officer (COO) effective December 1st, 2022. Anna has a strong track record in transforming and scaling growth-driven international organizations and will join Olink from Galderma where she has held several leadership positions with increasing responsibility over the past ten years, including General Manager/Head of Nordic, and senior roles in decision support and strategic planning.

Olink's current COO, Fredrik Netzel, will be appointed VP Operations, his role to include management of Olink's supply chain, a function of critical importance to Olink's success and differentiation. Carl Raimond has served as Olink's CCO since October 2020, previously serving as the Company's Senior Vice President of Sales beginning in August 2020. Prior to Olink, he served in various executive commercial leadership roles at PerkinElmer Inc. including Vice President and General Manager of Americas Sales and Service, as well as Global Vice President and General Manager of Sales and Service for the Discovery and Analytical Solutions Division.

Before this, he served as the Vice President and General Manager of the Americas Life Science Sales & Field Operations of Agilent Technologies Inc. Carl received his Bachelor of Arts in zoology from State University of New York College at Oswego, and his Master of Science in biology from State University of New York College at Brockport. Anna Marsell brings more than 15 years of international experience from the pharma and medtech industry with various roles in R&D, project management, sales and marketing, as well as company governance and general management. Her most recent role is General Manager for the Nordic region of Galderma, delivering sustainable organic growth and increased market share.

During her 10 years at Galderma she has held various senior leadership roles in global strategic marketing, product development, commercial operations, Uppsala Site management, as well as in strategic corporate governance when based in Galderma HQ in Lausanne, Switzerland. Prior to joining Galderma, Anna spent 7 years in various R&D and product marketing roles within medtech, focused on cardiovascular technology at Radi Medical Systems and St. Jude Medical in the U.S. and Sweden.

Anna is an inspirational leader with a strong track record in delivering outstanding commercial results, driving innovation and in managing high-performing teams. She holds a Master's in Molecular Biotechnology from Uppsala University and an Associate's Certificate in Project Management from The George Washington University and ESI International.